E. Berns

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

Marijn T. M. van Jaarsveld, Jozien Helleman, Antonius W.M. Boersma et al. · Oncogene · 2012 · 218 citations

Cisplatin Sensitivity, Medicine, Mir-141 Regulates Keap1 +10

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

P.M.L.H. Vencken, Mieke Kriege, D. Hoogwerf et al. · Annals of Oncology · 2011 · 212 citations · Full text

Medicine, Cancer Management, Gynecology +8

c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

E. Berns, J.G.M. Klijn, W L van Putten et al. · PubMed · 1992 · 206 citations

Her2/neu Genes, Breast Oncology, Medicine +13

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

P J van Diest, Peter A. van Dam, S.C. Henzen‐Logmans et al. · Journal of Clinical Pathology · 1997 · 199 citations · Full text

Tumor Biology, Prognostic Biomarkers, Tumoral Pathology +14

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

E. Berns, John A. Foekens, R. van Vossen et al. · PubMed · 2000 · 197 citations

Breast Oncology, Pathology, Complete Sequencing +19